Review of calculation of conditional power, predictive power and probability of success in clinical trials with continuous, binary and time-to-event endpoints

被引:0
|
作者
Madan G. Kundu
Sandipan Samanta
Shoubhik Mondal
机构
[1] Daiichi-Sankyo Inc. (DSI),
[2] TDK Corporation,undefined
[3] AstraZeneca,undefined
来源
Health Services and Outcomes Research Methodology | 2024年 / 24卷
关键词
B-value; Beta binomial; Clinical success; Conditional power; Normal prior; Predictive power of success (PPoS); Prior distribution; Probability of success (PoS); Trial success;
D O I
暂无
中图分类号
学科分类号
摘要
Assessment of study success using conditional power (CP), the predictive power of success (PPoS) and probability of success (PoS) is becoming increasingly common for resource optimization and adaption of trials in clinical investigation. Determination of these measures is often a non-trivial mathematical task. Further, the terminologies used across the literature are not consistent, and there is no consolidated presentation on this. We have made a structured presentation on these measures for both trial success and clinical success: first, we have summarized the expressions of CP, PPoS and PoS in a general setting and subsequently, expressions for these measures are obtained for continuous, binary, and time-to-event endpoints in single-arm and two-arm trial settings. Many of these expressions are previously published; however, some of the expressions are very new including the expressions for testing median of time-to-event endpoint in a single-arm trial. We have also shown that 1/(no.ofevents)\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$1/(\text{ no. } \text{ of } \text{ events})$$\end{document} consistently underestimates the variance of log(median) and alternative expression for variance was derived. Examples are given along with the comparison of CP and PPoS. Expressions presented in this paper are implemented in LongCART package in R and in R shiny app https://ppos.shinyapps.io/public/.
引用
收藏
页码:14 / 45
页数:31
相关论文
共 50 条
  • [1] Review of calculation of conditional power, predictive power and probability of success in clinical trials with continuous, binary and time-to-event endpoints
    Kundu, Madan G.
    Samanta, Sandipan
    Mondal, Shoubhik
    HEALTH SERVICES AND OUTCOMES RESEARCH METHODOLOGY, 2024, 24 (01) : 14 - 45
  • [2] A retrospective analysis of conditional power assumptions in clinical trials with continuous or binary endpoints
    Julia M. Edwards
    Stephen J. Walters
    Steven A. Julious
    Trials, 24
  • [3] A retrospective analysis of conditional power assumptions in clinical trials with continuous or binary endpoints
    Edwards, Julia M.
    Walters, Stephen J.
    Julious, Steven A.
    TRIALS, 2023, 24 (01)
  • [4] Hybridization of conditional and predictive power for futility assessment in sequential clinical trials with time-to-event outcomes: A resampling approach
    Yi, Jing
    Fang, Liang
    Su, Zheng
    CONTEMPORARY CLINICAL TRIALS, 2012, 33 (01) : 138 - 142
  • [5] Projection of power and events in clinical trials with a time-to-event outcome
    Royston, Patrick
    Barthel, Friederike M-S
    STATA JOURNAL, 2010, 10 (03): : 386 - 394
  • [6] Inconsistent Reporting and Definitions of Time-to-Event Endpoints in CAR T Clinical Trials: A Review
    Grady, Connor B.
    Li, Yimei
    Maude, Shannon L.
    Hexner, Elizabeth O.
    Frey, Noelle, V
    Porter, David L.
    Hwang, Wei-Ting
    TRANSPLANTATION AND CELLULAR THERAPY, 2025, 31 (04): : 271e1 - 271e13
  • [7] Power considerations for clinical trials using multivariate time-to-event data
    Hughes, MD
    STATISTICS IN MEDICINE, 1997, 16 (08) : 865 - 882
  • [8] Heterogeneous treatment effects in stratified clinical trials with time-to-event endpoints
    Beisel, Christina
    Benner, Axel
    Kunz, Christina
    Kopp-Schneider, Annette
    BIOMETRICAL JOURNAL, 2017, 59 (03) : 511 - 530
  • [9] A multistate platform model for time-to-event endpoints in oncology clinical trials
    Lin, Chih-Wei
    Nagase, Mario
    Doshi, Sameer
    Dutta, Sandeep
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2024, 13 (01): : 154 - 167
  • [10] Sample sizes for clinical trials with time-to-event endpoints and competing risks
    Schulgen, G
    Olschewski, M
    Krane, V
    Wanner, C
    Ruf, G
    Schumacher, M
    CONTEMPORARY CLINICAL TRIALS, 2005, 26 (03) : 386 - 396